- Home
- TCBS vs ELOX Comparison
TCBS vs ELOX Comparison
Compare TCBS & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TCBS | ELOX |
|---|---|---|
| Founded | 1934 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 60.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TCBS | ELOX |
|---|---|---|
| Price | $17.00 | $14.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 1.9K | ★ 19.7K |
| Earning Date | 11-06-2026 | 08-12-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 327.27 | 41.67 |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.72 | $10.00 |
| 52 Week High | $20.00 | $23.40 |
Technical Indicators
Market Signals| Indicator | TCBS | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 43.79 |
| Support Level | $16.87 | $13.98 |
| Resistance Level | $17.07 | $19.43 |
| Average True Range (ATR) | 0.16 | 1.34 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 11.11 | 21.56 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.